The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
CREB-binding protein in androgen receptor-mediated signaling
Open accessAbstract
CREB-binding protein (CBP) is a transcriptional coregulator that interacts with different DNA binding proteins and components of the general transcription machinery. CBP enhanced androgen receptor (AR)-dependent transcription under transient transfection conditions in CV-1 cells. The ligand binding domain (LBD) and residues 38–296 of the N-terminal region of AR are not required because the activity of a receptor mutant devoid of these domains was augmented by coexpressed CBP. There is physical interaction between AR and CBP in vivo , as judged by coimmunoprecipitation experiments from cell extracts. Consistent with the role of CBP as a coactivator for AR, the 12S E1A adenoviral protein that inactivates CBP function strongly inhibited AR-dependent transactivation. Exogenous CBP was also capable of overcoming the inhibitory effect of AR on AP-1 activity and diminished the mutual transcriptional repression between AR and NF-κB (RelA). Collectively, these data imply that transcriptional interference between AR and AP-1 or NF-κB is mediated, at least in part, through competition for intracellular CBP and that this coactivator serves as an integrator between androgen-mediated and other signaling pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Animal steroid hormones are known exert their actions via binding to their intracellular nuclear receptors [7], for example, estrogen binds to its nuclear estrogen receptors ERα and ERβ [8], androgens bind to androgen receptors (AR) [9], and glucocorticoids bind to glucocorticoid receptors [10].”
From G protein-coupled receptors function as cell membrane receptors for the steroid hormone 20-hydroxyecdysone (2020) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,394
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily
Oñate, S. A., Tsai, S. Y., Tsai, M., & O’Malley, B. W. (1995) · Science · doi:10.1126/science.270.5240.1354 · Cited by 2,398
Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
Phosphorylated CREB binds specifically to the nuclear protein CBP
Chrivia, J. C., Kwok, R. P. S., Lamb, N., Hagiwara, M., Montminy, M. R., & Goodman, R. H. (1993) · Nature · doi:10.1038/365855a0 · Cited by 2,052
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X., Ogryzko, V. V., Nishikawa, J., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,497
Nuclear protein CBP is a coactivator for the transcription factor CREB
Kwok, R. P. S., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bächinger, H. P., Brennan, R. G., Roberts, S. G. E., Green, M. R., & Goodman, R. H. (1994) · Nature · doi:10.1038/370223a0 · Cited by 1,443
Transcriptional activation: A complex puzzle with few easy pieces
Tjian, R., & Maniatis, T. (1994) · Cell · doi:10.1016/0092-8674(94)90227-5 · Cited by 1,108
Voegel, J. J., Heine, M. J., Zechel, C., Chambon, P., & Gronemeyer, H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00736.x · Cited by 1,080
Ray, A., & Prefontaine, K. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.752 · Cited by 1,064
Research works printed but not linked: 9
- M Truss, M Beato Endocr Rev 14, 459–479 (1993).
- K B Horwitz, T A Jackson, D L Bain, J K Richer, G S Takimoto, L Tung Mol Endocrinol 10, 1167–1177 (1996).
- A J Bannister, T Oehler, D Wilhelm, P Angel, T Kouzarides Oncogene 11, 2509–2514 (1995).
- R Janknecht, A Nordheim Oncogene 12, 1961–1969 (1996).
- J J Palvimo, P J Kallio, T Ikonen, M Mehto, O A Jänne Mol Endocrinol 7, 1399–1407 (1993).
- P J Kallio, H Poukka, A Moilanen, O A Jänne, J J Palvimo Mol Endocrinol 9, 1017–1028 (1995).
- J Drouin, M A Trifiro, R K Plante, M Nemer, P Eriksson, Ö Wrange Mol Cell Biol 9, 1266–1272 (1989).
- L L Heckert, E M Wilson, J H Nilson Mol Endocrinol 11, 1497–1506 (1993).
- M Pfahl Endocr Rev 14, 651–658 (1993).
Cited by
Sorted by citations
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,115
Steffan, J. S., Kazantsev, A. G., Spasić-Bošković, O., Greenwald, M., Zhu, Y., Goehler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,057
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 972
Androgen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
CREB-binding protein sequestration by expanded polyglutamine
McCampbell, A. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.14.2197 · Cited by 547
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Fu, M., Wang, C., Reutens, A. T., Wang, J., Angeletti, R. H., Siconolfi-Baez, L., Ogryzko, V. V., Avantaggiati, M. L., & Pestell, R. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000660200 · Cited by 417
FHL2, a novel tissue‐specific coactivator of the androgen receptor
Müller, J. M., Isele, U., Metzger, E., Rempel, A., Moser, M., Pscherer, A., Breyer, T., Holubarsch, C., Buettner, R., & Schüle, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.359 · Cited by 326
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Myung, J., Banuelos, C. A., Fernandez, J. G., Mawji, N. R., Wang, J., Tien, A. H., Yang, Y. C., Tavakoli, I., Haile, S., Watt, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66398 · Cited by 316
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Welti, J. C., Sharp, A., Brooks, N. A. N., Yuan, W., McNair, C. M., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gürel, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0751 · Cited by 292
Gao, N., Zhang, J., Rao, M. A., Case, T. C., Mirosevich, J., Wang, Y., Jin, R., Gupta, A., Rennie, P. S., & Matusik, R. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0020 · Cited by 288
Oettgen, P., Finger, E., Sun, Z., Akbarali, Y., Thamrongsak, U., Boltax, J., Grall, F., Dube, A., Weiss, A., Brown, L., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.2.1216 · Cited by 268
Alen, P., Claessens, F., Verhoeven, G., Rombauts, W., & Peeters, B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6085 · Cited by 268
The Androgen Receptor in Health and Disease
Μatsumoto, T., Sakari, M., Okada, M., Yokoyama, A., Takahashi, S., Kouzmenko, A., & Kato, S. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183656 · Cited by 275
Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length
Irvine, R. A. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.267 · Cited by 263
De Bosscher, K. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00297-6 · Cited by 264
Wnt signaling in triple negative breast cancer is associated with metastasis
Dey, N., Barwick, B. G., Moreno, C. S., Ordanic-Kodani, M., Chen, Z., Oprea-Ilies, G. M., Tang, W., Catzavelos, C., Kerstann, K. F., Sledge, G. W., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-537 · Cited by 263
Chmelar, R. S., Buchanan, G., Need, E. F., Tilley, W. D., & Greenberg, N. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.22365 · Cited by 260
Cross-talk between nuclear receptors and nuclear factor κB
Bosscher, K. D., Berghe, W. V., & Haegeman, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209935 · Cited by 250
Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids
Almawi, W., & Melemedjian, O. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0280069 · Cited by 242
Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
Bartsch, G., Rittmaster, R. S., & Klocker, H. (2000) · European Urology · doi:10.1159/000020181 · Cited by 238
Sex hormones and their receptors regulate liver energy homeostasis
Shen, M., & Shi, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/294278 · Cited by 239
Histone deacetylase inhibitors reduce polyglutamine toxicity
McCampbell, A., Taye, A. A., Whitty, L., Penney, E. B., Steffan, J. S., & Fischbeck, K. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261400698 · Cited by 239
Cross-talk between glucocorticoid receptor and AP-1
Herrlich, P. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204388 · Cited by 229
Lavery, D. N., & Mcewan, I. J. (2005) · Biochemical Journal · doi:10.1042/bj20050872 · Cited by 227
Moilanen, A., Poukka, H., Karvonen, U., Häkli, M., Jänne, O. A., & Palvimo, J. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5128 · Cited by 209
Self-citationDiversity in the mechanisms of gene regulation by estrogen receptors
Sánchez, R., Nguyen, D., Rocha, W., White, J. H., & Mader, S. (2002) · BioEssays · doi:10.1002/bies.10066 · Cited by 200
Gelman, L., Fruchart, J., & Auwerx, J. H. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050345 · Cited by 199
Almawi, W. Y., & Melemedjian, O. K. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.1.9 · Cited by 196
Androgen-Insensitivity Syndrome as a Possible Coactivator Disease
Adachi, M., Takayanagi, R., Tomura, A., Imasaki, K., Kato, S., Goto, K., Yanase, T., Ikuyama, S., & Nawata, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009213431205 · Cited by 192
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer
Gnanapragasam, V. J., Leung, H. Y., Pulimood, A., Neal, D. E., & Robson, C. N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2179 · Cited by 189
Li, Q., Herrler, M., Landsberger, N., Kaludov, N. K., Ogryzko, V. V., Nakatani, Y., & Wolffe, A. P. (1998) · The EMBO Journal · doi:10.1093/emboj/17.21.6300 · Cited by 183
Acetylation of nuclear receptors in cellular growth and apoptosis
Fu, M., Wang, C., Zhang, X., & Pestell, R. G. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.037 · Cited by 183
Topper, J. N., DiChiara, M. R., Brown, J. D., Williams, A. J., Falb, D., Collins, T., & Gimbrone, M. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9506 · Cited by 180
Ubc9 Interacts with the Androgen Receptor and Activates Receptor-dependent Transcription
Poukka, H., Aarnisalo, P., Karvonen, U., Palvimo, J. J., & Jänne, O. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.19441 · Cited by 174
Self-citationAberrant HOXC expression accompanies the malignant phenotype in human prostate.
Miller, G. J., Miller, H. L., van Bokhoven, A., Lambert, J. R., Werahera, P. N., Schirripa, O., Lucia, M. S., & Nordeen, S. K. (2003) · PubMed · Cited by 171
Fu, M., Wang, C., Wang, J., Zhang, X., Sakamaki, T., Yeung, Y. G., Chang, C., Hopp, T., Fuqua, S. A. W., Jaffray, E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3373-3388.2002 · Cited by 173
Self-citationSong, L.-N., Herrell, R., Byers, S., Shah, S., Wilson, E. M., & Gelmann, E. P. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1674-1687.2003 · Cited by 169
Androgen receptor signaling and mutations in prostate cancer
Koochekpour, S. (2010) · Asian Journal of Andrology · doi:10.1038/aja.2010.89 · Cited by 167
Narayanan, B. A., Narayanan, N. K., Re, G. G., & Nixon, D. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.10932 · Cited by 164
Recent advances in androgen receptor action
Lee, H.-J., & Chang, C. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2309-3 · Cited by 162
Li, P., Lee, H., Guo, S., Unterman, T. G., Jenster, G. W., & Bai, W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.104-118.2003 · Cited by 160
McEwan, I. J. (2004) · Endocrine-related cancer · doi:10.1677/erc.0.0110281 · Cited by 156
Svensson, C., Ceder, J. A., Iglesias‐Gato, D., Chuan, Y.-C., Pang, S., Bjartell, A. S., Merino-Martinez, R., Bott, L., Helczynski, L., Ulmert, D., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt921 · Cited by 154
Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor
Chesire, D. R., & Isaacs, W. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206049 · Cited by 151
Ras signaling in prostate cancer progression
Weber, M. J., & Gioeli, D. G. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10683 · Cited by 153
Prostate cancer: molecular biology of early progression to androgen independence.
Sadar, M. D., Hussain, M., & Bruchovsky, N. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060487 · Cited by 148
Fontes, J. D., Kanazawa, S., Jean, D., & Peterlin, B. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.941 · Cited by 144
Inhibition of Androgen Receptor (AR) Function by the Reproductive Orphan Nuclear Receptor DAX-1
Holter, E., Kotaja, N., Mäkelä, S., Strauss, L., Kietz, S., Jänne, O. A., Gustafsson, J.-Α., Palvimo, J. J., & Treuter, E. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.3.0804 · Cited by 144
Self-citationDeterminants of Receptor- and Tissue-Specific Actions in Androgen Signaling
Pihlajamaa, P., Sahu, B., & Jänne, O. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1034 · Cited by 144
Self-citationExpression of Androgen Receptor Coregulators in Prostate Cancer
Linja, M. J., Porkka, K. P., Kang, Z., Savinainen, K., Jänne, O. A., Tammela, T. L. J., Vessella, R. L., Palvimo, J. J., & Visakorpi, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0990-3 · Cited by 140
Self-citationAndrogen receptor phosphorylation: biological context and functional consequences
Koryakina, Y. A., Ta, H. Q., & Gioeli, D. G. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0472 · Cited by 136
Heterogeneous Expression and Functions of Androgen Receptor Co-Factors in Primary Prostate Cancer
Li, P., Yu, X., Ge, K., Melamed, J., Roeder, R. G., & Wang, Z. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64422-7 · Cited by 136
Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice
Abel, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.107 · Cited by 135
Androgen effects on bone metabolism: recent progress and controversies
Hofbauer, L. C., & Khosla, S. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1400271 · Cited by 135
Breast cancer: from estrogen to androgen receptor
Andò, S., Amicis, F. D., Rago, V., Carpino, A., Maggiolini, M., Panno, M., & Lanzino, M. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00105-3 · Cited by 130
p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6
Gingras, S., Simard, J., Groner, B., & Pfitzner, E. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.13.2722 · Cited by 129
Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia
Bartsch, G., Rittmaster, R., & Klocker, H. (2002) · World Journal of Urology · doi:10.1007/s00345-002-0248-5 · Cited by 128
Hypoxia in prostate cancer: A powerful shield against tumour destruction?
Marignol, L. H., Coffey, M. A., Lawler, M., & Hollywood, D. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.006 · Cited by 125
Androgen receptor coregulators: recruitment via the coactivator binding groove
van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J., & Jenster, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.007 · Cited by 122
Signal transduction in prostate cancer progression
Gioeli, D. G. (2005) · Clinical Science · doi:10.1042/cs20040329 · Cited by 117
Beta-catenin signaling in prostate cancer: an early perspective.
Chesire, D. R., & Isaacs, W. B. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100537 · Cited by 116
Zhou, X., Shen, X.-Q., & Shemshedini, L. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0237 · Cited by 114
Waddell, A. R., Huang, H., & Liao, D. (2021) · Cancers · doi:10.3390/cancers13122872 · Cited by 110
Sone, K., Hinago, M., Itamoto, M., Katsu, Y., Watanabe, H., Urushitani, H., Tooi, O., Guillette, L. J., & Iguchi, T. (2005) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2005.03.007 · Cited by 110
Berghe, W. V., Francesconi, E., Bosscher, K. D., Resche-Rigon, M., & Haegeman, G. (1999) · PubMed · Cited by 108
Discovery of Chemical Inhibitors of Human Bromodomains
Zhang, G., Smith, S. G., & Zhou, M. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00205 · Cited by 108
Androgen signaling and its interactions with other signaling pathways in prostate cancer
Kaarbø, M., Klokk, T. I., & Saatcioglu, F. (2007) · BioEssays · doi:10.1002/bies.20676 · Cited by 106
HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation
Jung, C., Kim, R.-S., Zhang, H., Lee, S., Sheng, H., Loehrer, P. J., Gardner, T. A., Jeng, M. H., & Kao, C. H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602631 · Cited by 104
A Coregulatory Role for the TRAP-Mediator Complex in Androgen Receptor-mediated Gene Expression
Wang, Q., Sharma, D., Ren, Y., & Fondell, J. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206061200 · Cited by 104
Inhibition of Androgen Receptor-Mediated Transcription by Amino-Terminal Enhancer of split
Yu, X., Li, P., Roeder, R. G., & Wang, Z. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4614-4625.2001 · Cited by 104
A Tissue-Specific Enhancer of the Prostate-Specific Membrane Antigen Gene, FOLH1
Watt, F., Martorana, A., Brookes, D., Ho, T., Kingsley, E. A., O’Keefe, D. S., Russell, P. J., Heston, W. D. W., & Molloy, P. L. (2001) · Genomics · doi:10.1006/geno.2000.6446 · Cited by 103
Shenk, J. L., Fisher, C. J., Chen, S., Zhou, X., Tillman, K. C., & Shemshedini, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103652200 · Cited by 103
Valentine, J. E., Kalkhoven, E., White, R., Hoare, S., & Parker, M. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002497200 · Cited by 102
Glucocorticoid Repression of AP-1 Is Not Mediated by Competition for Nuclear Coactivators
Bosscher, K. D., Berghe, W. V., & Haegeman, G. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.2.0591 · Cited by 94
Debes, J. D., Comuzzi, B., Schmidt, L. J., Dehm, S. M., Culig, Z., & Tindall, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2837 · Cited by 92
Chang, C., Yeh, S., Lee, S. O., & Chang, T. (2013) · Nuclear Receptor Signaling · doi:10.1621/nrs.11001 · Cited by 92
Hosohata, K., Li, P., Hosohata, Y., Qin, J., Roeder, R. G., & Wang, Z. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.19.7019-7029.2003 · Cited by 91
Regulation of vertebrate corticotropin-releasing factor genes
Yao, M., & Denver, R. J. (2007) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2007.01.046 · Cited by 86
Mayeur, G. L., Kung, W.-J., Martinez, A. D., Izumiya, C., Chen, D. J., & Kung, H.-J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413336200 · Cited by 86
Yang, Z., Chang, Y., Miyamoto, H., Ni, J., Niu, Y., Chen, Z.-D., Chen, Y., Yao, J. L., di Sant'Agnese, P. A., & Chang, C. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0104 · Cited by 83
Blankvoort, B. M. G., de Groene, E. M., Kreikamp, A. P., Witkamp, R. F., Rodenburg, R. J., & Aarts, J. M. M. J. G. (2001) · Analytical Biochemistry · doi:10.1006/abio.2001.5352 · Cited by 80
Malinen, M., Niskanen, E. A., Kaikkonen, M. U., & Palvimo, J. J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw855 · Cited by 82
Self-citationEpigenetic Mechanisms for Progression of Prostate Cancer
Rennie, P. S., & Nelson, C. C. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006121219097 · Cited by 80
Li, Q., Imhof, A., Collingwood, T. N., Urnov, F. D., & Wolffe, A. P. (1999) · The EMBO Journal · doi:10.1093/emboj/18.20.5634 · Cited by 78
Morimoto, S., Fernández‐Mejía, C., Romero-Navarro, G., Morales-Peza, N., & Díaz‐Sánchez, V. (2001) · Endocrinology · doi:10.1210/endo.142.4.8069 · Cited by 78
Chen, S.-Y., Cai, C., Fisher, C. J., Zheng, Z., Omwancha, J., Hsieh, C.-L., & Shemshedini, L. (2006) · Oncogene · doi:10.1038/sj.onc.1209705 · Cited by 78
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder
Boorjian, S. A., Heemers, H. V., Frank, I., Farmer, S. A., Schmidt, L. J., Sebo, T. J., & Tindall, D. J. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0124 · Cited by 76
Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1
Zhang, Y., Fondell, J. D., Wang, Q., Xia, X., Cheng, A., Lu, M. L., & Hamburger, A. W. (2002) · Oncogene · doi:10.1038/sj.onc.1205638 · Cited by 76
Yeh, S., Kang, H., Miyamoto, H., Nishimura, K., Chang, H., Ting, H., Rahman, M. M., Lin, H., Fujimoto, N., Hu, Y., et al. (1999) · Endocrine · doi:10.1385/endo:11:2:195 · Cited by 77
Thiruppathi, M., Palaniappan, M., & Balasubramanian, K. (2009) · Metabolism · doi:10.1016/j.metabol.2009.05.010 · Cited by 77
Comuzzi, B., Lambrinidis, L., Rogatsch, H., Godoy‐Tundidor, S., Knežević, N., Krhen, I., Mareković, Z., Bartsch, G. H., Klocker, H., Hobisch, A., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63814-x · Cited by 76
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers
Rau, K.-M., Kang, H.-Y., Cha, T.-L., Miller, S. A., & Hung, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01026 · Cited by 76
Poukka, H., Aarnisalo, P., Santti, H., Jänne, O. A., & Palvimo, J. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.571 · Cited by 74
Self-citationVerhovshek, T., Cai, Y., Osborne, M. C., & Sengelaub, D. R. (2009) · Endocrinology · doi:10.1210/en.2009-1036 · Cited by 73
Saitoh, M., Takayanagi, R., Goto, K., Fukamizu, A., Tomura, A., Yanase, T., & Nawata, H. (2002) · Molecular Endocrinology · doi:10.1210/me.16.4.694 · Cited by 73
Matsuda, T., Junicho, A., Yamamoto, T., Kishi, H., Korkmaz, K., Saatcioglu, F., Fuse, H., & Muraguchi, A. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4758 · Cited by 76
The androgen receptor: a potential target for therapy of prostate cancer
dos Santos, A. F., Huang, H., & Tindall, D. J. (2003) · Steroids · doi:10.1016/j.steroids.2003.10.005 · Cited by 74
Metadata
- Authors
- Aarnisalo, P., Palvimo, J. J., & Jänne, O. A.
- Affiliations
- University of Helsinki (FI)
- ORCID
- Palvimo, Jorma J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1998-03-03
- Volume
- 95
- Issue
- 5
- Pages
- 2122-2127
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC19270
- OpenAlex
- W2023929246
- Cited by
- 255
- References
- 56
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 2 · 2015: 8 · 2014: 3 · 2013: 9 · 2012: 6
- FWCI
- 23.10
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- CREB-binding protein, androgen receptor, transcriptional coactivator, AP-1, NF-κB, RelA, transcriptional repression, transcriptional interference, E1A protein, ligand-binding domain, protein-protein interaction, signaling pathway integration
- MeSH terms
- Animals, Binding Sites, Cell Line, Humans, Kinetics, Nuclear Proteins, Receptors, Androgen, Receptors, Glucocorticoid, Transcription Factors, Transcription, Genetic, Transfection, Protein Engineering, Signal Transduction, Transcriptional Activation, Trans-Activators, Sequence Deletion, Transcription Factor AP-1, COS Cells, CREB-Binding Protein, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review